Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Abstract: Computer-aided methods and computer-based systems designed to elicit information from imaging data of a volume of in vivo tissue to facilitate clinical determinations and/or pathological evaluation.

Abstract: A method, a statistics subsystem, and a system use a combination of commercially available high speed memory and high density low speed memory to mitigate cost, space, control, and power issues associated with storing counters for statistics updates, while meeting the growing width and depth needs of multi-hundred gigabit Carrier Class data network devices. The method, statistics subsystem, and system offer a Counter Management Algorithm (CMA) that relies on rollover bits stored within data of counters. An update to the low speed memory is substantially faster than a rollover time for the counter in the high speed memory thereby allowing statistics to be cached in the high speed memory while updates take place to the low speed memory.

Abstract: Computer-aided methods and computer-based systems designed to elicit information from imaging data of a volume of in vivo tissue to facilitate clinical determinations and/or pathological evaluation.

Abstract: A system for management of multimedia content having a processor and memory configured to execute software instructions for implementing a content management component operative to upload the multimedia content and to create at least one compilation from the multimedia content, a market management component operative to assign market-specific data to the compilation, and a store builder resource component operative to generate one or more online stores for promotion of the compilation having the assigned market-specific data.

Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.

Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

Abstract: A system for tracking and evaluating a colonoscopy procedure performed using an endoscope includes a tracking subsystem, a processing subsystem and a display subsystem. The tracking subsystem provides information representative of the location of the endoscope within a patient's colon during the procedure. The processing subsystem generates visualization metrics from images produced by the endoscope during the procedure. The display subsystem is coupled to the tracking and processing subsystems to generate a visual display of the patient's colon with information representative of the visualization metrics at associated colon locations.

Abstract: A system for management of multimedia content having a processor and memory configured to execute software instructions for implementing a content management component operative to upload the multimedia content and to create at least one compilation from the multimedia content, a market management component operative to assign market-specific data to the compilation, and a store builder resource component operative to generate one or more online stores for promotion of the compilation having the assigned market-specific data.

Abstract: A system and method for rating the validity of multiple data processing algorithms A1-An on a set of multi-dimensional input data I where P1-Pn is the output data produced by the competing algorithms. Processing steps include: (1) computing the Fourier Transform or the phase congruence of the input data I, (2) computing the Fourier Transform or the phase congruence of the output data P1-Pn, (3) computing the phase of the data computed at step 1, (4) computing the phases of the data computed at step 2, and (5) computing a similarity metric, such as the normalized cross correlation of each phase computed at step 4 with the corresponding phase computed at step 3. The similarity metrics computed at step 5 can be ordered to provide a ranking of the algorithm validity.

Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.

Abstract: Techniques for generating tissue support structure are presented. A curved minimal surface shape is determined as a template for generating a tissue support structure. The determined curved minimal surface shape is numerically or functionally defined to create data representing the shape. The data is exported to a rapid prototyping system to generate a plurality of tissue support structures having a curved minimal surface. The tissue support structure can have a pore sub-section and a non-pore sub-section divided by a non-intersecting two-sided surface. A number of characteristics of the tissue support structure can be modulated including porosity and mechanical strength.

Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.